US5041447A - Oxetanocin-related compounds and pharmaceutical compositions containing them - Google Patents

Oxetanocin-related compounds and pharmaceutical compositions containing them Download PDF

Info

Publication number
US5041447A
US5041447A US07/325,230 US32523089A US5041447A US 5041447 A US5041447 A US 5041447A US 32523089 A US32523089 A US 32523089A US 5041447 A US5041447 A US 5041447A
Authority
US
United States
Prior art keywords
compound
solvent
chloroform
methanol
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/325,230
Other languages
English (en)
Inventor
Seiichi Saito
Shigeru Hasegawa
Katsutoshi Takahashi
Nobuyoshi Shimada
Jun-ichi Seki
Hiroo Hoshino
Yukihiro Nishiyama
Kenichi Matsubara
Takemitsu Nagahata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Assigned to NIPPON KAYAKU KABUSHIKI KAISHA, A CORP. OF JAPAN reassignment NIPPON KAYAKU KABUSHIKI KAISHA, A CORP. OF JAPAN ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: HASEGAWA, SHIGERU, HOSHINO, HIROO, MATSUBARA, KENICHI, NAGAHATA, TAKEMITSU, NISHIYAMA, YUKIHIRO, SAITO, SEIICHI, SEKI, JUN-ICHI, SHIMADA, NOBUYOSHI, TAKAHASHI, KATSUTOSHI
Application granted granted Critical
Publication of US5041447A publication Critical patent/US5041447A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members

Definitions

  • This invention relates to novel oxetanocin-related compounds and salts thereof. More particularly, this invention relates to oxetanocin-related compounds and salts thereof having activities such as antiviral activity and the like and being expectedly useful as medicine and the like.
  • Oxetanocin itself is well known, because it is disclosed in Journal of Antibiotics, Vol. 39, No. 11, Pages 1623-25 (1986), EP-A 2 -0182312, etc.
  • This invention relates to oxetanocin-related compounds represented by the following general formula ##STR3## wherein R 1 , Y and B have the following meanings: (a) R 1 represents --CH 2 OH or --CH 2 OCO--(alkyl),
  • Y represents ##STR4## provided that R 2 represents --H, --OH or --CH 2 OH and R 3 represents --H, --OH, halogen atom, --CH 2 OH, lower alkyl group which may be substituted by halogen atoms, --CH 2 --N 3 , --N 3 , --COOH, --NH 2 , --CH 2 OSO 3 H or --CH 2 OCO--(lower alkyl),
  • the oxetanocin-related compounds of this invention exhibit an antiviral action and the like and are expectedly useful as a therapeutic drug for various viral diseases.
  • Y represents ##STR6## provided that R 2 represents --H, --OH or --CH 2 OH and R 3 represents --H, --OH, halogen atom, --CH 2 OH, lower alkyl group which may be substituted by halogen atoms, --CH 2 --N 3 , --N 3 , --COOH, --NH 2 , --CH 2 OSO 3 H or --CH 2 OCO--(lower alkyl),
  • alkyl group usable in the invention include alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, heptadecyl, octadecyl, eicosyl and the like.
  • alkyl groups may be any of straight chain type and branched chain type, and may contain a substituent, if desired.
  • alkyl groups having about 1 to 6 carbon atoms can be referred to.
  • the lower alkyl group may be any of straight chain type and branched chain type.
  • Lower alkyl groups substituted by halogen atom for example, fluorine atom, bromine atom, chlorine atom
  • halogen atom for example, fluorine atom, bromine atom, chlorine atom
  • purine base residue residues of purine derivatives linked to an oxetane ring at the 9-position of purine skeleton represented by the following formula: ##STR7## can be referred to.
  • the purine base residue include adenine residue, guanine residue, xanthine residue, hypoxanthine residue, 2,6-diaminopurine residue, and the like.
  • the compound of this invention is produced by eliminating the protecting group from a protected oxetanocin-related compound represented by the following formula (I-a): ##STR40##
  • R 1 ', Y' and B have the following meanings: (a) R 1 ' represents --CH 2 O--P 1 (P 1 is protecting group) or R 1 , provided that R 1 represents --CH 2 OH or --CH 2 OCO--(alkyl);
  • Y' represents --CH 2 O--P 1 (P 1 is protecting group) or Y, provided that Y represents ##STR41## wherein R 2 is --H, --OH or --CH 2 OH, R 3 ' is --CH 2 O--P 1 (P 1 is protecting group) or R 3 , and R 3 is --H, --OH, halogen atom, --CH 2 OH, lower alkyl group which may be substituted by halogen atoms, --CH 2 --N 3 , --N 3 , --COOH, --NH 2 , --CH 2 OSO 3 H or --CH 2 OCO--(lower alkyl);
  • (c) B represents a residue of purine base of which functional group may optionally be protected
  • a compound represented by the following general formula (I'): ##STR43## wherein B is as defined above and R 3 " represents --H or --OH, which is one of the typical examples of the oxetanocin-related compound of this invention, can be synthesized by eliminating the protecting group from a protected oxetanocin-related compound represented by the following general formula (II): ##STR44## wherein P 1 and B are as defined above, or by dehydroxylating the protected oxetanocin-related compound and thereafter eliminating the protecting group.
  • the protected oxetanocin-related compound represented by general formula (II) can be obtained by converting the sugar part of Oxetanocin A, Oxetanocin H, Oxetanocin X, Oxetanocin G or 2-amino-Oxetanocin A [Journal of Antibiotics, Vol. 40, No. 12, Pages 1788-90 (1987)] by a chemical method.
  • P 1 is as defined above and T represents thionocarbonate group.
  • Step 1 The hydroxyl groups in 2'--CH 2 OH and 3'--CH 2 OH of N(6)-protected oxetanocin 1 are selectively protected with some protecting group.
  • protecting group (P 1 and P 2 ) of compounds 2 and 3 formyl group, (lower alkyl)-carbonyl groups optionally substituted by halogen atom, lower alkoxy group, benzoyl group or the like (for example, acetyl, chloroacetyl, trichloroacetyl, methoxyacetyl, pivalotyl, phenoxyacetyl, trityloxyacetyl and the like), acyl groups (for example, benzoyl and the like) and optionally substituted lower alkyl groups including unsubstituted lower alkyl groups such as t-butyl and the like and substituted lower alkyl groups such as unsubstituted trityl and substituted trityls [for example, (lower alkoxy)-trityls such as monomethoxytrityl, dimethoxytrityl, trimethoxytrityl and the like] can be referred to
  • silyl type protecting groups i.e. silyl groups having various substituents (for example, trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl and the like) can also be referred to.
  • the above-mentioned protecting group can be introduced according to hitherto known methods.
  • a protecting group which can be eliminated effectively afterwards is selected.
  • Compound 2 and compound 3 can be separated from each other by column chromatography.
  • Step 2 This is a step for sulfonylating the hydroxyl group of 2'--CH 2 OH of compound 2.
  • the sulfonylating agent used for this purpose include alkyl- and aryl-sulfonyl halogenides such as methane-sulfonyl chloride, p-toluenesulfonyl chloride, 2,4,6-triisopropylbenzenesulfonyl chloride and the like.
  • Step 3 This is a step for forming an olefin by treating compound 4 with a base.
  • a base alkali metal lower alcholates such as t-butoxypotassium and the like are preferably used.
  • Step 4 In this step, the olefin compound 5 is oxidized (Lemieux-von Rudloff oxidation) with potassium permanganate or sodium periodate to form a ketone compound and then reducing the latter with a metal hydride to form a secondary hydroxyl group (Compound 6).
  • the metal hydride usable for this purpose include sodium boron hydride, sodium trimethoxyboron hydride, sodium boron hydride cyanide, lithium triethoxyaluminum hydride, lithium aluminum hydride and the like.
  • Step 5 This is a step for converting the resulting secondary alcohol to a thionocarbonate.
  • a thionocarbonate As an agent for producing thionocarbonate, phenyl chlorocarbonothionate can be used.
  • Step 6 In this step, compound 7 is treated with tributyltin hydride and ⁇ , ⁇ '-azobis-isobutyronitrile to eliminate the thionocarbonate part.
  • Step 7 This is a step for eliminating the protecting groups P 1 and P 2 .
  • a basic compound exercising no substantial influence upon the oxetane ring is used. Its amount may be any amount, so far as the amount adopted is enough to cause a substantial elimination of the protecting groups. Preferably, it is used in at least an amount theoretically equivalent to the protected oxetanocin-related compound.
  • As the reaction temperature a temperature not exceeding the boiling point of the used solvent (for example, about -40° C. to about 150° C.) can be adopted. Usually, the reaction is carried out at a temperature of 0° C. to 100° C.
  • the protecting group P 1 is a silyl type protecting group (silyl group having various substituents)
  • an ammonium compound such as tetra-n-butylammonium fluoride can be used in tetrahydrofuran, for example.
  • an alkali metal alkoxide such as sodium methoxide, ammonia water, and the like can be used.
  • a compound of general formula (I) wherein B is adenine residue (A) and Y is ##STR48## can be produced by oxidizing compound 5 to form a compound represented by the following formula 9: ##STR49## and then eliminating the protecting groups therefrom.
  • a compound of general formula (I) wherein B is adenine residue (A) and Y is ##STR50## (compound No. 4) can be obtained by eliminating the protecting groups from compound 5.
  • compound No. 3 can be obtained by eliminating the protecting groups from compound 6, and compounds wherein Y is ##STR51## such as compound No. 5 can be obtained by halogenating compound 2 and then eliminating the protecting groups.
  • a compound of formula (I) wherein B is adenine residue (A) and R 1 is --CH 2 OCO--(alkyl) can be obtained by acylating a compound of the following formula 3': ##STR52## in the usual manner and then eliminating the protecting group P 1 .
  • the protecting group P 1 must be capable of elimination under a condition not affecting the acyl group.
  • a prefereable protecting group P 1 is silyl group, for example.
  • B is a residue of other bases such as guanine residue (G), hypoxanthine residue (H), xanthine residue (X) or 2,6-diaminopurine residue
  • the intended compounds can be obtained similarly by treating the corresponding compounds according to the above-mentioned procedure.
  • the temperature at which OXT-A is treated with adenosine deaminase is not critical, so far as the enzyme can act. However, it is usually about 10° C. to about 50° C., and preferably about 15° C. to about 40° C.
  • the solvent used in this reaction is not critical, so far as it does not disturb the action of the enzyme. Usually, however, aqueous solvents such as water and the like are used. Preferably, the reaction is carried out in the neighborhood of neutral pH by the use of a buffer solution.
  • an oxetanocin-related compound represented by the following formula (I-e): ##STR56## wherein R 1 ' represents --CH 2 OH or --CH 2 O--P 1 (P 1 is protecting group), B represents a residue of purine base of which functional group may optionally be protected, and Y" represents ##STR57## or its salt can be obtained by reducing an oxetanocin-related compound represented by the following formula (I-d): ##STR58## wherein R 1 ' and B are as defined above and Y' represents ##STR59## or its salt in an inert solvent by a catalytic reduction using Pd/black or by a reduction using a boron hydride compound such as alkali metal boron hydride.
  • the inert solvents used in the catalytic reduction are for example water, an acetic acid and a lower alcohol such as methanol or ethanol and that used in the reduction by a boron hydride compound is acetonitrile, tetrahydrofuran or a lower alcohol.
  • the reaction temperature may be a conventional temperature.
  • the reaction can be carried out in the temperature range from about 0° C. to the boiling point of the solvent, and preferably from about 5° C. to about 80° C.
  • the catalytic reduction is usually used, to obtain the compound of ##STR60## from the compound of ##STR61##
  • the reduction using a boron hydride compound is usually used to obtain the compound of ##STR62## ps from the compound of
  • the compounds of this invention exhibit an antiviral activity against DNA virus or(and) RNA virus and the like, they are expectedly usable as an antiviral agent.
  • the viruses controllable with the compounds of this invention include retrovirus including human immunodeficiency virus, Adenovirus, Parvovirus, Papovavirus, Poxvirus, Herpesvirus, Cytomegalovirus, hepatitis B virus, Togavirus, Arenavirus, and the like.
  • R 1 is --CH 2 OH or --CH 2 OCO--(alkyl)
  • Y is ##STR63##
  • R 2 is --H or --OH
  • R 3 is --H, halogen atom, --CH 2 OH, --CH 2 --N 3 , --CH 2 --F or --N 3 are preferable, because they have an intense antiviral activity.
  • Anti-HIV human immunodeficiency virus
  • MT-4 cell (about 100,000 cells/ml) was added into a 24 well tray, and then 100 microliters of a solution containing a predetermined quantity of a compound of this invention was added. After culturing it at 37° C. for 5 hours in 5% (v/v) carbon dioxide incubator, 10 3 to 10 4 infection units of HIV was added and cultured for 4 days. Then, a part of the cultured fluid was coated onto a slide glass and immobilized with acetone, after which development of virus antigen was observed by indirect fluorescent antibody method.
  • a serum of AIDS patient was used.
  • FITC-labelled human IgG was used.
  • Anti-cytomegalovirus activity was determined in the following manner.
  • a 35 mm ⁇ dish containing a single layer of human fetal fibroblasts was infected with 100 PFU (plaque forming units) of cytomegalovirus (A0169 strain).
  • PFU plaque forming units
  • cytomegalovirus A0169 strain
  • a medium (0.5% agarose, 2% fetal calf serum) containing a varied concentration of the compound of this invention was superposed thereon, and the whole was cultured at 37° C. for 10 days in 5% (v/v) carbon dioxide incubator, after which the formation of plaque was measured.
  • the results are shown in Table 3 in terms of 50% inhibitory value (IC 50 ).
  • a cultured liver cell strain HB 611 producing and releasing active hepatitis B virus [Proc. Natl. Acad. Sci. USA, 84 (1987), p. 444] was cultured at 37° C. in modified Eagle medium (GIBCO) in the presence of 10% fetal calf serum, 200 micrograms/ml of G418, 100 u/ml of Penicillin and 100 u/ml of Streptomycin with 5% carbon dioxide. It was inoculated into 6-well plate at a rate of 5 ⁇ 10 4 cells/well (35 mm ⁇ ). When 50% confluent was reached in one or two days, a predetermined quantity of the compound of this invention was added and the culture was continued.
  • GEBCO modified Eagle medium
  • the medium was exchanged with a fresh medium containing the same test chemical at the same concentration at intervals of every 3 days, and the culture was continued for 15 days in the total. Then, the medium was removed, and the cell was treated with 0.5 ml of lysis buffer (10 mM Tris-HCl, pH 7.8/5 mM Na 2 EDTA, 1% SDS/0.1 mg/ml Pronase K) at 37° C. for one hour to obtain a solution.
  • the DNA thus obtained was purified by RNase treatment, phenol-chloroform treatment, and ethanol precipitation method.
  • 5 micrograms of DNA was subjected to Hind III treatment, and DNA pattern was analyzed by southern blot method by using 32 P-labelled hepatitis B virus DNA as a probe. The results are shown in Table 4.
  • the compound of this invention exhibits a remarkable growth-inhibitory activity on HIV with only a small extent of cell denaturation. Accordingly, the compounds of this invention are expected to be effectively usable as a therapeutic drug for AIDS.
  • NMR nuclear magnetic resonance spectrum
  • MS mass analysis spectrum
  • IR infrared absorption spectrum
  • the solvent is distilled off under reduced pressure to obtain a light yellow syrup. It is passed through a column packed with 20 g of silica gel, and it is eluted with chloroform-methanol (20:1).
  • the solvent is distilled off under reduced pressure from the reaction mixture, the residue is diluted with 10 ml of water and it is extracted twice with each 10 ml portions of chloroform.
  • the chloroform extract is washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate.
  • the chloroform extract is washed with saturated aqueous solution of sodium chloride and dried over anhydorus sodium sulfate. After filtering off the sodium sulfate, the solvent is distilled off under reduced pressure to obtain a light yellow syrup. It is separated by silica gel column chromatography (60 ml, chloroform-methanol 50:1). Then, it is subjected to silica gel TLC [developing solvent: chloroform-methanol (20:1)]. Fractions having Rf value of about 0.79 are collected and the solvent is distilled off under reduced pressure to obtain 309.4 mg (77.6%) of Compound 5 as a colorless powder.
  • the chloroform extract is washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. After filtering off the sodium sulfate, the solvent is distilled off under reduced pressure.
  • the solvent is distilled off under reduced pressure to obtain a syrup.
  • the syrup is purified by silica gel column chromatography (20 ml, chloroform-methanol 50:1). Then, the purified product is subjected to silica gel thin layer chromatography (TLC) (developing solvent: chloroform-methanol 20:1), fractions having Rf value of about 0.567 are collected, and the solvent is distilled off therefrom under reduced pressure to obtain 53.8 mg (82.7%) of Compound 7 as a colorless powder.
  • TLC silica gel thin layer chromatography
  • Elimination of protecting group A solution of tetrabutylammonium fluoride in tetrahydrofuran (0.3 ml, 1.05M) is added to a solution of 58 mg of crude Compound 8 in 3.5 ml of tetrahydrofran, and the resulting mixture is stirred at room temperature for one hour. The solvent is distilled off from the reaction mixture under reduced pressure, and the residue is stirred at 60° C. for one hour together with 2 ml of methanol and 4 ml of concentrated ammonia water. After distilling off the solvent from the reaction mixture under reduced pressure, the residue is dissolved into 3 ml of methanol, mixed with 200 mg of silica gel and methanol is distilled off under reduced pressure.
  • the residue is subjected to a silica gel column chromatography (25 ml) previously equilibrated with chloroform-methanol (8:1) and eluted with chloroform-methanol (8:1, 4:1).
  • the eluted product is subjected to silica gel TLC (developing solvent: chloroform-methanol, 4:1), fractions having Rf value of about 0.44 are collected and the solvent is distilled off therefrom under reduced pressure.
  • the residue is dissolved into aqueous methanol (80%) and purified by column chromatography using 100 ml of Sephadex® LH-20 equilibrated with the same solvent as above.
  • the purified product is subjected to the same silica gel TLC as above, fractions having Rf value of about 0.44 are collected and the solvent is distilled off therefrom under reduced pressure to obtain 5.6 mg (17.2%) of Compound No. 1 as a colorless powder.
  • the chloroform extract is washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. After filtering off the sodium sulfate, the solvent is distilled off under reduced pressure to obtain a syrup.
  • the syrup is purified by silica gel column chromatography (20 ml, chloroform-methanol 40:1). The purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol 20:1), fractions having Rf value of about 0.73 are collected and the solvent is distilled off therefrom under reduced pressure to obtain 78.7 mg of a residue.
  • the chloroform extract is washed with saturated aqueous solution of sodium chloride and dried over anhydorus sodium sulfate. After filtering off the sodium sulfate, the solvent is distilled off under reduced pressure to obtain a syrup.
  • the syrup is purified by silica gel column chromatography (20 ml, chloroform-methanol 20:1). Then, the purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol 20:1), fractions having Rf value of about 0.13 are collected, from which the solvent is distilled off under reduced pressure to obtain 35 mg of a residue (protected compound of Compound No. 7). Protecting groups are eliminated from the protected compound in the same manner as in 1-6 of Example 1 to obtain 17.8 mg (72.4%) of Compound No. 7 as a colorless powder.
  • the purified product is subjected to silica gel TLC (chloroform-methanol, 5:1), fractions having Rf value of about 0.5 are collected, the solvent is distilled off therefrom under reduced pressure, and the residue is purified by silica gel column chromatography (20n ml, chloroform-methanol, 10:1) to obtain 1.0 mg of Compound No. 10.
  • Adenosine deaminase (29 microliters, 42.3 units) (manufactured by Sigma Co., EC 3.5.4.4) is added to a solution of 20.4 mg of Compound No. 3 in 10.2 ml of 1/10M phosphate buffer, and the mixture is stirred at 27° C. for 5 days.
  • the reaction mixture is passed through a column packed with 30 ml of MCI® GEL CHP20P to have the product adsorbed on the column. After washing the column with water, the adsorbed matter is eluted with 90 ml of methanol containing 20% water.
  • the eluted product is subjected to silica gel TLC (Art.
  • 100 ml of a medium (pH 7.0) containing 0.3% of meat extract, 1.0% of peptone and 0.7% of sodium chloride is dividingly poured into 500 ml Erlenmeyer flasks and sterilized in autoclave at 120° C. for 20 minutes.
  • One platinum loop quantity of Escherichia coli NIHJ is inoculated into each of the flasks and subjected to aerobic shaking culture at 37° C. for 18 hours. Then, 1,000 ml of the culture fluid is centrifuged at 10,000 r.p.m. for 10 minutes to collect the alive cell.
  • the cell After twice or thrice washing the cell with an equal volume of 1/20M phosphate buffer (pH 7.0), it is suspended into 100 ml of the same buffer as above. Then, 50 mg of Compound No. 3 is added to the suspension and reacted with shaking at 37° C. for 18 hours, after which the reaction mixture is heated at 100° C. for 5 minutes to stop the reaction. The reaction mixture is centrifuged under the same conditions as above, and the resulting supernatant is passed through a column packed with 50 ml of MCI® GEL CHP20P to have the product adsorbed on the column.
  • 1/20M phosphate buffer pH 7.0
  • the Adenosine deaminase used in this Example may be a commercial product, of which one concrete example is EC 3.5.4.4 manufactured by Sigma Co. Apart from it, products collected from animal tissues, cultured microorganisms, adenosine deaminase collected from them, and the like may all be usable regardless of their origin, so far as they are known to have a similar ability. A purified enzyme is not needed for this invention. When an enzyme originated from microorganism is to be used, a cultured product of microorganis (cell) obtained by culturing an organism having an ability to produce Adenosine deaminase in a nutrient medium can be used as it is.
  • microorganisms Apart from them, crude enzyme samples prepared from acetone-dried product of microorganism, ground product of microorganism cell, its ultrasonic wave-treated product, its product treated with surfactant, toluene or lysozyme and the like, as well as cells immobilized on natural and synthetic polymers, are also usable similarly. Concretely speaking, the following microorganisms can be used.
  • Compound No. 1 (3.5 mg) is dissolved into 1.75 ml of 1/10M phosphate buffer, to which is added 10 microliters (14.6 units) of Adenosine deaminase (EC 3.5.4.4, manufactured by Sigma Co.). The resulting mixture is stirred at 37° C. for 4.5 hours.
  • the reaction mixture is passed through a column packed with 6.5 ml of MCI® GEL CHP 20 P to have the product adsorbed thereon. After washing the column with water, the adsorbed matter is eluted with 20 ml of methanol containing 20% of water.
  • the eluted product is subjected to silica gel TLC (Art. 5715, manufactured by MERCK) [developing solvent: 1-butanol-acetic acid-water (4:1:2)], fractions having Rf value of about 0.36 are collected and the solvent is distilled off therefrom to obtain 3.34 mg (yield 95.0%) of Compound No. 13 as a colorless powder.
  • the purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol 10:1), fractions having Rf value of about 0.51 are collected and the solvent is distilled off therefrom under reduced pressure to obtain 27.1 mg (yield 16.6%) of Compound ⁇ 11 as a colorless powder Further, fractions having Rf value of about 0.64 are collected and the solvent is distilled off under reduced pressure to obtain 42.0 mg (yield 25.8%) of Compound ⁇ 11 '.
  • silica gel TLC developing solvent: chloroform-methanol 10:1
  • the purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol, 20:1), fractions having Rf value of about 0.38 are collected and the solvent is distilled off therefrom under reduced pressure to obtain 16.2 mg (yield 47.2%) of compound ⁇ 12 as a syrup.
  • the syrup is dissolved into 6 ml of anhydrous dimethylformamide under a stream of nitrogen, 2.3 mg of 4-dimethylaminopyridine, 209.8 microliters of triethylamine and 382.2 mg of 4,4'-dimethoxytrityl chloride are added, and the resulting mixture is stirred in the dark at room temperature overnight. After distilling off the solvent under reduced pressure, the syrupy residue is purified by silica gel column chromatography (20 ml, chloroform-methanol, 100:1).
  • the purified product is subjected to silica gel TLC (developing solvent: chloroform-methahol, 50:1), fractions having Rf value of about 0.73 are collected, and the solvent is distilled off under reduced pressure to obtain 230 mg (yield 55.7%) of compound ⁇ 14 .
  • the purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol, 50:1), fractions having Rf value of about 0.07 are collected, from which the solvent is distilled off under reduced pressure to obtain 137.2 mg (yield 75.3%) of Compound ⁇ 15 as a red-colored power.
  • silica gel TLC developing solvent: chloroform-methanol, 50:1
  • Sulfur trioxide-pyridine complex (19.6 mg) is added to a solution of 30 mg of Compound ⁇ 18 in 2 ml of N,N-dimethyl-formamide, and stirred at room temperature for 3 hours. Then, 100 microliters of 1.0M solution of tetrabutylammonium fluoride in tetrahydrofuran is added and stirred for 1.5 hours, after which the solvent is distilled off. The, 2 ml of water is added, and the mixture is passed through a 10 ml column of cation-exchange resin Dowex® 50 W ⁇ 8 (H 30 ) at 5° C. Fractions developing a color with sulfuric acid are collected and neutralized with 0.1N solution of sodium hydroxide.
  • the chloroform extract layer is washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. After filtering off the sodium sulfate and distilling off the solvent, the syrupy residue is purified by silica gel column chromatography (20 ml, chloroform-methanol, 20:1). Then, the purified product is subjected to silica gel TLC (developing solvent: chloroform-methanol, 20:1), fractions having Rf value of about 0.70 and developing a color with 2,4-dinitrophenylhdrazine are collected and the solvent is distilled off therefrom to obtain 43.1 mg (yield 86.3%) of Compound ⁇ 22 as a syrup.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
US07/325,230 1988-03-23 1989-03-17 Oxetanocin-related compounds and pharmaceutical compositions containing them Expired - Fee Related US5041447A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP63-67253 1988-03-23
JP6725388 1988-03-23
JP23365088 1988-09-20
JP63-233650 1988-09-20

Publications (1)

Publication Number Publication Date
US5041447A true US5041447A (en) 1991-08-20

Family

ID=26408430

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/325,230 Expired - Fee Related US5041447A (en) 1988-03-23 1989-03-17 Oxetanocin-related compounds and pharmaceutical compositions containing them

Country Status (4)

Country Link
US (1) US5041447A (fr)
EP (1) EP0334250A3 (fr)
KR (1) KR890014539A (fr)
AU (1) AU601640B2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202459A (en) * 1989-11-07 1993-04-13 Nippon Kayaku Kabushiki Kaisha Process for producing cyclobutane derivative
US5214048A (en) * 1987-05-19 1993-05-25 Nippon Kayaku Kabushiki Kaisha Oxetanocins
US5283331A (en) * 1990-12-20 1994-02-01 Nippon Kayaku Kabushiki Kaisha 2-halogeno-oxetanocin A and phosphoric ester thereof
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
US20030144385A1 (en) * 1999-07-09 2003-07-31 Vickers Thomas M. Oligomeric dispersant
US20030181579A1 (en) * 1999-07-09 2003-09-25 Michael Porsch Oligomeric dispersant
US20050215568A1 (en) * 2003-11-21 2005-09-29 Howell Amy R Substituted oxetanes, method of making, and method of use thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86381A0 (en) * 1987-05-19 1988-11-15 Nippon Kayaku Kk Oxetanocins and pharmaceutical compositions containing the same
US5597824A (en) * 1987-11-03 1997-01-28 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US5420276A (en) * 1987-11-03 1995-05-30 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US5179084A (en) * 1989-04-10 1993-01-12 Nippon Kayaku Kabushiki Kaisha Antiviral phosphoric acid esters of oxetanocins
JPH03173896A (ja) * 1989-09-08 1991-07-29 Nippon Kayaku Co Ltd 新規オキセタノシン誘導体、その塩およびその用途
JPH03115294A (ja) * 1989-09-29 1991-05-16 Nippon Kayaku Co Ltd オキセタノシン誘導体の新規製造法
IE904378A1 (en) 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182315A2 (fr) * 1984-11-20 1986-05-28 Nippon Kayaku Kabushiki Kaisha Antibiotique NK84-0218, compositions pharmaceutiques le contenant et procédé pour sa production
JPS62208295A (ja) * 1986-03-07 1987-09-12 Nippon Kayaku Co Ltd ヒポキサンチン塩基を有する新規化合物およびその製造法
EP0291917A2 (fr) * 1987-05-19 1988-11-23 Nippon Kayaku Kabushiki Kaisha Oxétanocines
JPS63303993A (ja) * 1987-06-03 1988-12-12 Nippon Kayaku Co Ltd オキセタン型ｎ−グリコシド構造を有する化合物の製造法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182315A2 (fr) * 1984-11-20 1986-05-28 Nippon Kayaku Kabushiki Kaisha Antibiotique NK84-0218, compositions pharmaceutiques le contenant et procédé pour sa production
US4743689A (en) * 1984-11-20 1988-05-10 Nippon Kayaku Kabushiki Kaisha Antibiotic derivative of adenine
JPS62208295A (ja) * 1986-03-07 1987-09-12 Nippon Kayaku Co Ltd ヒポキサンチン塩基を有する新規化合物およびその製造法
US4845215A (en) * 1986-03-07 1989-07-04 Nippon Kayaku Kabushiki Kaisha Purine derivative
EP0291917A2 (fr) * 1987-05-19 1988-11-23 Nippon Kayaku Kabushiki Kaisha Oxétanocines
JPS63303993A (ja) * 1987-06-03 1988-12-12 Nippon Kayaku Co Ltd オキセタン型ｎ−グリコシド構造を有する化合物の製造法

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Hoshino et al., J. Antibiot., vol. 40(7), pp. 1077 1078 (07/87). *
Hoshino et al., J. Antibiot., vol. 40(7), pp. 1077-1078 (07/87).
J. of Antibiotics, vol. 39(11), pp. 1623 1625, Shimada et al. *
J. of Antibiotics, vol. 39(11), pp. 1623-1625, Shimada et al.
Niitsuma et al., Chemical Abstracts, vol. 109: 38158q (1988). *
Niitsuma et al., Tetrahedron Letters, vol. 28(34), pp. 3967 3970 (08/87). *
Niitsuma et al., Tetrahedron Letters, vol. 28(34), pp. 3967-3970 (08/87).
Norbeck et al., J. Am. Chem. Soc., vol. 110(21), pp. 7217 7218 (10/88). *
Norbeck et al., J. Am. Chem. Soc., vol. 110(21), pp. 7217-7218 (10/88).
Shimada et al., J. Antibiot., vol. 40(12), pp. 1788 1780 (12/87). *
Shimada et al., J. Antibiot., vol. 40(12), pp. 1788-1780 (12/87).

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214048A (en) * 1987-05-19 1993-05-25 Nippon Kayaku Kabushiki Kaisha Oxetanocins
US5202459A (en) * 1989-11-07 1993-04-13 Nippon Kayaku Kabushiki Kaisha Process for producing cyclobutane derivative
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
US5283331A (en) * 1990-12-20 1994-02-01 Nippon Kayaku Kabushiki Kaisha 2-halogeno-oxetanocin A and phosphoric ester thereof
US20030144385A1 (en) * 1999-07-09 2003-07-31 Vickers Thomas M. Oligomeric dispersant
US20030181579A1 (en) * 1999-07-09 2003-09-25 Michael Porsch Oligomeric dispersant
US20050215568A1 (en) * 2003-11-21 2005-09-29 Howell Amy R Substituted oxetanes, method of making, and method of use thereof
US7351827B2 (en) 2003-11-21 2008-04-01 The University Of Connecticut Substituted oxetanes, method of making, and method of use thereof
US20080139566A1 (en) * 2003-11-21 2008-06-12 Howell Amy R Substituted oxetanes, method of making, and method of use thereof
US7687500B2 (en) 2003-11-21 2010-03-30 The University Of Connecticut Substituted oxetanes, method of making, and method of use thereof

Also Published As

Publication number Publication date
EP0334250A3 (fr) 1991-10-16
AU601640B2 (en) 1990-09-13
AU3160189A (en) 1989-09-28
KR890014539A (ko) 1989-10-24
EP0334250A2 (fr) 1989-09-27

Similar Documents

Publication Publication Date Title
US5041447A (en) Oxetanocin-related compounds and pharmaceutical compositions containing them
US5200534A (en) Process for the preparation of taxol and 10-deacetyltaxol
EP0122707B1 (fr) Agents antiviraux difluorés
US4965374A (en) Process for and intermediates of 2',2'-difluoronucleosides
US6162826A (en) Genipin derivative having anti hepatitis B virus activity
EP0115350B1 (fr) Rebeccamycine et son procédé de préparation
US4730058A (en) Sialosylceramides and production method thereof
EP0143557B1 (fr) Dérivés de l'acide griséolique
EP0214708B1 (fr) Dérivés d'acide griséolique, leur préparation et leur utilisation
US5811408A (en) 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides
FR2500838A1 (fr) Derives de neplanocine a
EP0061283A1 (fr) Agents antiviraux, leur préparation et emploi
AU751470B2 (en) Novel antibacterial compounds
US20070191598A1 (en) Process for Preparing Gemcitabine and Associated Intermediates
US5006646A (en) Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
US5028598A (en) Oxetanocin derivatives and their salts as well as use thereof
US4244874A (en) 3,8-Dioxo-scirpen-4β,15-diol esters and their use as antitumor agents
Ogawa et al. Synthesis of several optically active O-methyl-inosamines and-inosadiamines from l-quebrachitol
JPH09249690A (ja) ４’−チオアラビノプリンヌクレオシド
US5574021A (en) Methods of treatment using 2',3'-dideoxy-2',2'-difluoronucleosides
US5817639A (en) Purine 4'-thioarabinonucleosides
EP0318060B1 (fr) Dérivés de l'acide griséolique, leur préparation et leur utilisation
AU2006325622B2 (en) A manufacturing process of 2',2'-difluoronucleoside and intermediate
JP3806456B2 (ja) 癌細胞転移抑制物質６−（トリクロロアセタミド）−４，５−ジヒドロキシピペリジン−３−カルボン酸および６−グアニジノ−４，５−ジヒドロキシピペリジン−３−カルボン酸とその関連物質
HU203552B (en) Process for producing oxetanocin derivatives and pharmaceutical composition containing them

Legal Events

Date Code Title Description
AS Assignment

Owner name: NIPPON KAYAKU KABUSHIKI KAISHA, A CORP. OF JAPAN,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SAITO, SEIICHI;HASEGAWA, SHIGERU;TAKAHASHI, KATSUTOSHI;AND OTHERS;REEL/FRAME:005036/0432

Effective date: 19890307

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19990820

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362